KR100958293B1 - 테오필린에 의해 표적 특이적 rna 치환 활성이 조절되는알로스테릭 트랜스―스플라이싱 그룹 i 리보자임 - Google Patents
테오필린에 의해 표적 특이적 rna 치환 활성이 조절되는알로스테릭 트랜스―스플라이싱 그룹 i 리보자임 Download PDFInfo
- Publication number
- KR100958293B1 KR100958293B1 KR1020080028483A KR20080028483A KR100958293B1 KR 100958293 B1 KR100958293 B1 KR 100958293B1 KR 1020080028483 A KR1020080028483 A KR 1020080028483A KR 20080028483 A KR20080028483 A KR 20080028483A KR 100958293 B1 KR100958293 B1 KR 100958293B1
- Authority
- KR
- South Korea
- Prior art keywords
- ribozyme
- theophylline
- trans
- splicing
- rna
- Prior art date
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/124—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes based on group I or II introns
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/124—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes based on group I or II introns
- C12N2310/1241—Tetrahymena
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3519—Fusion with another nucleic acid
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/9005—Enzymes with nucleic acid structure; e.g. ribozymes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- General Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (17)
- 삭제
- 삭제
- 삭제
- hTERT(human Telomerase reverse transcriptase) RNA를 특이적으로 표적하며, 3' 엑손에는 반딧불 유래 루시퍼라제 수용체 유전자를 함유하는 것을 특징으로 하는 테오필린에 의해 RNA 치환 활성이 조절되는 알로스테릭 트랜스-스플라이싱 그룹 I 리보자임.
- 제4항에 있어서, 상기 리보자임은 서열번호 1로 표시되는 AS300 △P9 8T, 서열번호 2로 표시되는 AS100 Mu-P9 6T8T 또는 서열번호 3으로 표시되는 AS300 W-P9 6T8T인 것을 특징으로 하는 리보자임.
- 제4항에 따른 리보자임을 인코딩하는 발현벡터.
- 제6항에 있어서, 상기 발현벡터는 서열번호 4로 표시되는 pSEAP AS300 Delta P9 8T-Luci, 서열번호 5로 표시되는 pSEAP AS100 Mu-P9 6T8T-Luci 또는 서열번호 6으로 표시되는 pSEAP AS300 W-P9 6T8T-Luci인 것을 특징으로 하는 발현벡터.
- hTERT(human Telomerase reverse transcriptase) RNA를 특이적으로 표적하 며, 3' 엑손에는 HSV-TK(herpes simplex virus thymidine kinase) 세포사 유전자를 함유하는 것을 특징으로 하는 테오필린에 의해 RNA 치환 활성이 조절되는 알로스테릭 트랜스-스플라이싱 그룹 I 리보자임.
- 제8항에 있어서 상기 리보자임은 서열번호 7로 표시되는 AS300 W-P9 6T8T-TK인 것을 특징으로 하는 리보자임.
- 제8항에 따른 리보자임을 포유류 세포에서 발현하는 발현벡터.
- 제10항에 있어서, 상기 발현벡터는 서열번호 8로 표시되는 pAvQ-Theo-Rib21AS-TK(KCCM 10935P)인 것을 특징으로 하는 발현벡터.
- 제4항 또는 제8항에 따른 리보자임 및 테오필린을 포함하는 것을 특징으로 하는 유전자 발현 유도제.
- 제6항 또는 제10항에 따른 발현벡터 및 테오필린을 포함하는 것을 특징으로 하는 유전자 발현 유도제.
- 제4항 또는 제8항에 따른 리보자임 및 테오필린을 포함하는 것을 특징으로 하는 암 진단제.
- 제6항 또는 제10항에 따른 발현벡터 및 테오필린을 포함하는 것을 특징으로 하는 암 진단제.
- 제4항 또는 제8항에 따른 리보자임 및 테오필린을 포함하는 것을 특징으로 하는 유전자 치료제.
- 제6항 또는 제10항에 따른 발현벡터 및 테오필린을 포함하는 것을 특징으로 하는 유전자 치료제.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080028483A KR100958293B1 (ko) | 2008-03-27 | 2008-03-27 | 테오필린에 의해 표적 특이적 rna 치환 활성이 조절되는알로스테릭 트랜스―스플라이싱 그룹 i 리보자임 |
US12/442,258 US20110003883A1 (en) | 2008-03-27 | 2008-12-16 | Allosteric trans-splicing group i ribozyme whose activity of target-specific rna replacement is controlled by theophylline |
JP2010506095A JP4908631B2 (ja) | 2008-03-27 | 2008-12-16 | テオフィリンによって標的特異的rna置換活性が調節されるアロステリックトランス−スプライシンググループiリボザイム |
PCT/KR2008/007440 WO2009119965A1 (en) | 2008-03-27 | 2008-12-16 | Allosteric trans-splicing group i ribozyme whose activity of target-specific rna replacement is controlled by theophylline |
CN200880000802.5A CN101688231B (zh) | 2008-03-27 | 2008-12-16 | 由茶碱调控其靶特异性核糖核酸的取代活性的变构反式剪接i型核酶 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080028483A KR100958293B1 (ko) | 2008-03-27 | 2008-03-27 | 테오필린에 의해 표적 특이적 rna 치환 활성이 조절되는알로스테릭 트랜스―스플라이싱 그룹 i 리보자임 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20090103105A KR20090103105A (ko) | 2009-10-01 |
KR100958293B1 true KR100958293B1 (ko) | 2010-05-19 |
Family
ID=41114125
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020080028483A KR100958293B1 (ko) | 2008-03-27 | 2008-03-27 | 테오필린에 의해 표적 특이적 rna 치환 활성이 조절되는알로스테릭 트랜스―스플라이싱 그룹 i 리보자임 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20110003883A1 (ko) |
JP (1) | JP4908631B2 (ko) |
KR (1) | KR100958293B1 (ko) |
CN (1) | CN101688231B (ko) |
WO (1) | WO2009119965A1 (ko) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016154962A1 (zh) * | 2015-04-01 | 2016-10-06 | 华侨大学 | 一种核酶型基因表达调控元件及其应用 |
DE112016003047B4 (de) | 2015-11-17 | 2022-10-27 | Highlight Therapeutics, S.L. | Neue pharmazeutische zusammensetzung umfassend partikel umfassend einen komplex eines doppelsträngigen polyribonukleotids und eines polyalkylenimins |
EP3436590A4 (en) * | 2016-04-01 | 2019-12-04 | National University of Singapore | TRANSFERING RNA (TSRNA) |
JP2020520368A (ja) | 2017-05-17 | 2020-07-09 | ビオンコテック セラピューティクス エセ.エレ | 二本鎖ポリリボヌクレオチドとポリアルキレンイミンとの複合体を含む粒子を含む新規な医薬組成物 |
CN108753818B (zh) * | 2018-04-24 | 2022-01-28 | 深圳市第二人民医院 | RNA信号连接器、靶mRNA翻译调控方法、逻辑门及应用 |
CN109852650B (zh) * | 2018-12-18 | 2020-12-01 | 江南大学 | 一种由茶碱调控的人工适体酶及应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0008966D0 (en) * | 2000-04-13 | 2000-05-31 | Imp College Innovations Ltd | Vectors for gene therapy |
JP2004515219A (ja) * | 2000-06-15 | 2004-05-27 | ボード・オブ・リージェンツ,ザ・ユニヴァーシティ・オヴ・テキサス・システム | 調節可能な触媒活性な核酸 |
EP1297146A2 (en) * | 2000-06-23 | 2003-04-02 | Maxygen, Inc. | Novel chimeric promoters |
WO2005001039A2 (en) * | 2003-05-29 | 2005-01-06 | Creighton University | Ribozyme-regulated small inhibitory rna (sirna) production and methods of use thereof |
US7598077B2 (en) * | 2003-06-05 | 2009-10-06 | The United States Of America As Represented By The Department Of Health And Human Services | Compositions and methods for enhancing differential expression |
-
2008
- 2008-03-27 KR KR1020080028483A patent/KR100958293B1/ko active IP Right Grant
- 2008-12-16 WO PCT/KR2008/007440 patent/WO2009119965A1/en active Application Filing
- 2008-12-16 US US12/442,258 patent/US20110003883A1/en not_active Abandoned
- 2008-12-16 JP JP2010506095A patent/JP4908631B2/ja active Active
- 2008-12-16 CN CN200880000802.5A patent/CN101688231B/zh active Active
Non-Patent Citations (5)
Title |
---|
논문 1: Science * |
논문 2: Nucleic Acids Res. * |
논문 3: FEBS Lett. * |
논문 4: Mol. Ther. * |
논문 5: Clin. Cancer Res. * |
Also Published As
Publication number | Publication date |
---|---|
KR20090103105A (ko) | 2009-10-01 |
CN101688231B (zh) | 2014-02-19 |
JP2010522572A (ja) | 2010-07-08 |
US20110003883A1 (en) | 2011-01-06 |
JP4908631B2 (ja) | 2012-04-04 |
CN101688231A (zh) | 2010-03-31 |
WO2009119965A1 (en) | 2009-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2021250992B2 (en) | Compositions and methods for directing proteins to specific loci in the genome | |
KR100958293B1 (ko) | 테오필린에 의해 표적 특이적 rna 치환 활성이 조절되는알로스테릭 트랜스―스플라이싱 그룹 i 리보자임 | |
KR102648489B1 (ko) | Crispr/cas-매개 유전자 조절을 위한 화학적으로 변형된 가이드 rna | |
US6165715A (en) | Expression systems | |
KR20170070238A (ko) | 단백질 내로의 비-천연 아미노산의 혼입 | |
KR20220133999A (ko) | 변형된 뉴클레오티드들을 갖는 닫힌 선형 dna | |
US7741113B2 (en) | Cell-specific molecule and method for importing DNA into osteoblast nuclei | |
CA2501708C (en) | Mammalian artificial chromosome | |
CN103834692A (zh) | 一种用于表达lncRNA的慢病毒载体及其应用 | |
US6120994A (en) | Antioxidant responsive element | |
US7235362B2 (en) | Compositions and methods for protein isolation | |
US6468754B1 (en) | Vector and method for targeted replacement and disruption of an integrated DNA sequence | |
KR101791296B1 (ko) | 알츠하이머병 관련 돌연변이 유전자를 포함하는 발현 카세트, 벡터, 및 이를 이용하여 형질전환된 세포주 | |
CN117460830A (zh) | 用于眼部转基因表达的组合物和方法 | |
CA2687844A1 (en) | Tumor suppressor gene screening using rna interference libraries and method of treatment | |
KR20230054840A (ko) | rAAV 비리온의 유도 생산을 위한 안정화된 세포주 | |
Miyagawa et al. | The regulation of membrane cofactor protein (CD46) expression by the 3′ untranslated region in transgenic mice | |
CN106749678A (zh) | Her2 car重组慢病毒载体及其构建方法与应用 | |
KR101825844B1 (ko) | 색소를 발현하는 바실러스 속 균주 및 이의 제조 방법 | |
KR102346159B1 (ko) | 고효율 발현 벡터 및 이의 용도 | |
CN112996914A (zh) | 基于载体VTvaf17的基因治疗 | |
CN114836461B (zh) | 表达胶原蛋白酶的重组质粒、酵母菌株及其发酵培养基和发酵培养方法 | |
WO2014049580A2 (en) | Assay to monitor autophagy, a method and kit thereof | |
JP4268169B2 (ja) | 胚性幹細胞の自己複製決定因子 | |
KR20230169221A (ko) | 비-바이러스 상동성 매개 말단 접합 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130513 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20140416 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20150417 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20160325 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20180411 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20190408 Year of fee payment: 10 |